Loading
Life sciences · Journal article
Journal of Medicinal Food · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction associated with obesity frequently coincides with hepatic lipid accumulation; however, effective preventive strategies are scarce. This study evaluated the dose-dependent effects of Lactobacillus delbrueckii subsp. lactis CKDB001 in mice with high-fat diet (HFD)–induced obesity. Male C57BL/6J mice were assigned to a normal diet, HFD, or HFD with CKDB001 at one of three different doses (LL1, 5.0 × 10 8; LL2, 1.0 × 10 9; LL3, 5.0 × 10 9 CFU/day). Following 4 weeks of HFD feeding, CKDB001 was administered daily for 8 weeks while maintaining the HFD. Among the doses, LL2 demonstrated the most consistent outcomes, including reductions in body weight gain and liver and adipose tissue weights, without affecting food or energy intake. LL2 also decreased serum total cholesterol, alanine aminotransferase levels, hepatic cholesterol content, and histological scores for steatosis, fibrosis, and nonalcoholic fatty liver disease. Although changes in hepatic triglyceride and lipid metabolism-related gene expression were minimal, LL2 and LL3 enhanced colonic Zo-1 and occludin mRNA expression compared to the HFD group, suggesting a potential gut-associated transcriptional response to CKDB001 supplementation.